Discovery of Arylfuran and Carbohydrate Derivatives from the BraCoLi Library as Potential Zika Virus NS3pro Inhibitors
Approved
Classifications
MinEdu publication type
A1 Journal article (peer-reviewed)
Definition
Article
Target group
Scientific
Peer reviewed
Peer-reviewed
Article type
Journal article
Host publication type
Journal
Publication channel information
Title of journal/series
Future pharmacology
ISSN (electronic)
2673-9879
ISSN (linking)
2673-9879
Publication forum ID
92635
Publication forum level
0
Internationality
Yes
Detailed publication information
Publication year
2025
Reporting year
2025
Journal/series volume number
5
Journal/series issue number
1
Article number
9
DOI
10.3390/futurepharmacol5010009
Language of publication
English
Co-publication information
International co-publication
Yes
Co-publication with a company
No
Availability
Link to online publication
Classification and additional information
MinEdu field of science classification
317 Pharmacy
Keywords
antiviral activity; arylfuran derivative; consensus docking; MTT; NS3(pro); Zika virus
Funding information
Funding information in the publication
This research was funded by Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior (CAPES), grant number 88887.664178/2022-00; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), grant number 152673/2024-5; Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), grant numbers BPD-00076-22, APQ-01818-21, APQ-00789-22, and REDE-00110-23; and UFMG intramural funds. J.S.A., R.B.d.O., and R.S.F. are researchers awarded with CNPq Productivity Scholarship. T.K. is funded by the German Center for Infection Research (DZIF, TTU06.716).
Source database ID
WoS ID
WOS:001482956600001